Global End Stage Renal Disease (ESRD) Drug Market Segments 2024, Forecast To 2033
5 Mar, 2024
The end-stage renal disease (ESRD) drug market has seen rapid expansion, increasing from $116.32 billion in 2023 to $132.86 billion in 2024, with a 14.2% CAGR. This growth is attributed to factors such as the increasing incidence of ESRD, an aging population, and improved access to healthcare services. Looking ahead to 2028, the market is projected to reach $232.13 billion, sustaining a 15.0% CAGR. Anticipated growth drivers include emerging therapies, rising healthcare expenditure, and trends such as advancements in treatment modalities and precision medicine approaches.
Global End Stage Renal Disease (ESRD) Drug Market Key Driver
The end-stage renal disease (ESRD) drug market will experience growth due to rising cases of obesity and diabetes. The number of obese individuals is expected to rise to 1,025 million by 2030, contributing to the demand for ESRD drugs.
Get A Free Sample Of The Global End Stage Renal Disease (ESRD) Drug Market ReportGlobal End Stage Renal Disease (ESRD) Drug Market Segments
The end stage renal disease (esrd) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkalaemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the end stage renal disease (ESRD) drug market in 2023. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major End Stage Renal Disease (ESRD) Drug Industry Players
Pfizer Inc.; AstraZeneca plc; Sanofi SA; Astellas Pharma Inc.; Novartis AG; Fresenius SE & Co. KGaA; Takeda Pharmaceutical Company Limited; F. Hoffmann-La Roche Ltd.; Kissei Pharmaceutical Co. Ltd.; Baxter International Inc.; AbbVie Inc.; Amgen Inc.; Akebia Drugs Inc.; Bayer AG; Bristol-Myers Squibb Company; B. Braun SE; Asahi Kasei Medical Co. Ltd.; Cantel Medical Corp.; Nikkiso Co. Ltd.; Abbott Laboratories; Alere Inc.; Siemens Healthcare AG; Roche Diagnostics Corporation; Beckman Coulter Inc.; Becton Dickinson And Co.; Thermo Fisher Scientific Inc.; BioMerieux SA; Bio-Rad Laboratories; Randox Laboratories; Enzo Biochem Inc.; Merck Co. & KGaA; QIAGEN N.V.; PerkinElmer Inc.; Tosoh Corporation; Eurolyser Diagnostica GmbH
Get The Full Global End Stage Renal Disease (ESRD) Drug Market ReportAIOps End Stage Renal Disease (ESRD) Drug Market Overview
End stage renal disease (ESRD) drug is a drug used to treat a medical illness in which a person's kidneys stop working permanently, requiring a kidney transplant or a regular regimen of long-term dialysis to protect life. It is crucial in treating and preventing secondary problems in individuals with chronic renal disease (CKD).
End Stage Renal Disease (ESRD) Drug Global Market Report 2023 provides data on the global end stage renal disease (esrd) drug market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The end stage renal disease (esrd) drug market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.